MedDay Pharmaceuticals
http://www.medday-pharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MedDay Pharmaceuticals
WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention
Highlights will include data for Summit/Akeso’s PD-L1/VEGF bispecific versus Keytruda, ADCs and DLL3-targeting drugs for SCLC, and agents against EGFR, HER2 and Trop-2 in NSCLC.
Flagship Plans To Distribute New Fund To About Two Dozen Companies
The venture capital firm announced a $3.6bn raise for Fund VIII and side funds, which it plans to invest across human health, AI and sustainability-focused companies.
BeiGene Among Chinese Firms Eyeing Less Crowded SCLC Sector In US Trials
BeiGene, Junshi, Henlius are studying their PD-1, TIGIT and BTLA-targeting assets in US trials for the relatively less crowded indication of small cell lung cancer.
FDA Postmarket Guidance Hammers Home Positions On Foreign Trials, Real-World Evidence
US agency emphasizes and formalizes long-standing viewpoints on hot topics including accelerated approval in a new guidance on postmarket study diversity.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- MedDay Pharmaceuticals SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice